These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
828 related articles for article (PubMed ID: 9120678)
1. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess. Whorwood CB; Stewart PM J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678 [TBL] [Abstract][Full Text] [Related]
2. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Stewart PM; Krozowski ZS; Gupta A; Milford DV; Howie AJ; Sheppard MC; Whorwood CB Lancet; 1996 Jan; 347(8994):88-91. PubMed ID: 8538347 [TBL] [Abstract][Full Text] [Related]
3. Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population. Quinkler M; Bappal B; Draper N; Atterbury AJ; Lavery GG; Walker EA; DeSilva V; Taylor NF; Hala S; Rajendra N; Stewart PM Mol Cell Endocrinol; 2004 Mar; 217(1-2):143-9. PubMed ID: 15134813 [TBL] [Abstract][Full Text] [Related]
4. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Mune T; Rogerson FM; Nikkilä H; Agarwal AK; White PC Nat Genet; 1995 Aug; 10(4):394-9. PubMed ID: 7670488 [TBL] [Abstract][Full Text] [Related]
5. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. Li A; Li KX; Marui S; Krozowski ZS; Batista MC; Whorwood CB; Arnhold IJ; Shackleton CH; Mendonca BB; Stewart PM J Hypertens; 1997 Dec; 15(12 Pt 1):1397-402. PubMed ID: 9431844 [TBL] [Abstract][Full Text] [Related]
6. [A case of apparent mineralocorticoid excess caused by type 2 11 beta- hydroxysteroid dehydrogenase deficiency]. Morineau G; Pascoe L; Marc JM; Caillette A; Krozowski Z; Corvol P; Fiet J Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1111-5. PubMed ID: 9404418 [TBL] [Abstract][Full Text] [Related]
7. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. Odermatt A; Dick B; Arnold P; Zaehner T; Plueschke V; Deregibus MN; Repetto H; Frey BM; Frey FJ; Ferrari P J Clin Endocrinol Metab; 2001 Mar; 86(3):1247-52. PubMed ID: 11238516 [TBL] [Abstract][Full Text] [Related]
8. A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. Kitanaka S; Katsumata N; Tanae A; Hibi I; Takeyama K; Fuse H; Kato S; Tanaka T J Clin Endocrinol Metab; 1997 Dec; 82(12):4054-8. PubMed ID: 9398712 [TBL] [Abstract][Full Text] [Related]
9. Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency. Nikkilä H; Tannin GM; New MI; Taylor NF; Kalaitzoglou G; Monder C; White PC J Clin Endocrinol Metab; 1993 Sep; 77(3):687-91. PubMed ID: 8370690 [TBL] [Abstract][Full Text] [Related]
10. Two homozygous mutations in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. Carvajal CA; Gonzalez AA; Romero DG; González A; Mosso LM; Lagos ET; Hevia Mdel P; Rosati MP; Perez-Acle TO; Gomez-Sanchez CE; Montero JA; Fardella CE J Clin Endocrinol Metab; 2003 Jun; 88(6):2501-7. PubMed ID: 12788846 [TBL] [Abstract][Full Text] [Related]
11. 11 beta-Hydroxysteroid dehydrogenase: a link between the dysregulation of cortisol metabolism and hypertension. Donovan SJ Br J Biomed Sci; 1999; 56(3):215-25. PubMed ID: 10824333 [TBL] [Abstract][Full Text] [Related]
12. [Syndrome of apparent mineralocorticoid excess caused by a deficiency of 11 beta-hydroxysteroid dehydrogenase: clinical and genetic study in a Chilean family followed for 19 years]. Rodríguez JA Rev Med Chil; 2000 Jan; 128(1):17-26. PubMed ID: 10883518 [TBL] [Abstract][Full Text] [Related]
14. 11 beta-Hydroxysteroid dehydrogenase. Stewart PM; Krozowski ZS Vitam Horm; 1999; 57():249-324. PubMed ID: 10232052 [TBL] [Abstract][Full Text] [Related]
15. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. Atanasov AG; Ignatova ID; Nashev LG; Dick B; Ferrari P; Frey FJ; Odermatt A J Am Soc Nephrol; 2007 Apr; 18(4):1262-70. PubMed ID: 17314322 [TBL] [Abstract][Full Text] [Related]
16. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. Stewart PM; Murry BA; Mason JI J Clin Endocrinol Metab; 1994 Aug; 79(2):480-4. PubMed ID: 8045966 [TBL] [Abstract][Full Text] [Related]
17. Molecular basis for hypertension in the "type II variant" of apparent mineralocorticoid excess. Li A; Tedde R; Krozowski ZS; Pala A; Li KX; Shackleton CH; Mantero F; Palermo M; Stewart PM Am J Hum Genet; 1998 Aug; 63(2):370-9. PubMed ID: 9683587 [TBL] [Abstract][Full Text] [Related]
18. Molecular analysis of 11 beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. White PC; Mune T; Rogerson FM; Kayes KM; Agarwal AK Steroids; 1997 Jan; 62(1):83-8. PubMed ID: 9029720 [TBL] [Abstract][Full Text] [Related]
19. [11 beta-hydroxysteroid-dehydrogenase: characteristics and the clinical significance of a key enzyme in cortisol metabolism]. Kerstens MN; Dullaart RP Ned Tijdschr Geneeskd; 1999 Mar; 143(10):509-14. PubMed ID: 10321259 [TBL] [Abstract][Full Text] [Related]